Wilhelmus Egbertus Arnout de Witte

Wilhelmus Egbertus Arnout de Witte

Auto-generated profile, based on publicly available information

Wilhelmus Egbertus Arnout de Witte

ESQlabs GmbH, Am Sportplatz 7, 26683 Saterland, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Drug Discovery Today
Verified
Journal Article
Closed access
DSDoris A. Schuetz
Doris A. Schuetz
WWWilhelmus Egbertus Arnout de Witte
Wilhelmus Egbertus Arnout de Witte
YWYin Cheong Wong
Yin Cheong Wong
BKBernhard Knasmueller
Bernhard Knasmueller
LRLars Richter
Lars Richter
GEGerhard Ecker
Gerhard Ecker

1 October 2016 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
WWWilhelmus E.A. de Witte
Wilhelmus E.A. de Witte
MDMeindert Danhof
Meindert Danhof
PGPiet H. van der Graaf
Piet H. van der Graaf
ELElizabeth De Lange
Elizabeth De Lange

3 March 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IBIlze Bot
Ilze Bot
NZNatalia V. Ortiz Zacarías
Natalia V. Ortiz Zacarías
WWWilhelmus E. A. de Witte
Wilhelmus E. A. de Witte
HVHenk de Vries
Henk de Vries
PSPeter J. van Santbrink
Peter J. van Santbrink
LHLaura Heitman
Laura Heitman
CC Chemokine Receptor 2 (CCR2) and its endogenous ligand CCL2 are involved in a number of diseases, including atherosclerosis. Several CCR2 antagonists have been developed as potential therapeutic agents, however theirin vivoclinical efficacy was limited. In this report, we aimed to determine whether 15a, an antagonist with a long residence time on the human CCR2, is effective in inhibiting the development of atherosclerosis in a mouse disease model. First, radioligand binding assays were performed to determine affinity and binding kinetics of 15a on murine CCR2. To assess thein vivoefficacy, western-type diet fed apoE−/−mice were treated daily with 15a or vehicle as control. Treatment with 15a reduced the amount of circulating CCR2+monocytes and the size of the atherosclerotic plaques in both the carotid artery and the aortic root. We then showed that the long pharmacokinetic half-life of 15a combined with the high drug concentrations ensured prolonged CCR2 occupancy. These data render 15a a promising compound for drug development and confirms high receptor occupancy as a key parameter when targeting chemokine receptors.

21 July 2011 in Organic Letters
Verified
Journal Article
Closed access
MWMarthe Walvoort
Marthe Walvoort
WWWilbert de Witte
Wilbert de Witte
JDJesse van Dijk
Jesse van Dijk
JDJasper Dinkelaar
Jasper Dinkelaar
GLGerrit Lodder
Gerrit Lodder
GMGijsbert A. van der Marel
Gijsbert A. van der Marel

20 October 2015 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
WWWilhelmus Ea de Witte
Wilhelmus Ea de Witte
YWYin Cheong Wong
Yin Cheong Wong
INIndira Nederpelt
Indira Nederpelt
LHLaura Heitman
Laura Heitman
MDMeindert Danhof
Meindert Danhof
ELElizabeth De Lange
Elizabeth De Lange
Introduction: Drug-target binding kinetics are major determinants of the time course of drug action for several drugs, as clearly described for the irreversible binders omeprazole and aspirin. This...

1 November 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
WWW.E.A. de Witte
W.E.A. de Witte
GVG. Vauquelin
G. Vauquelin
PGP.H. van der Graaf
P.H. van der Graaf
ELElizabeth De Lange
Elizabeth De Lange
The influence of drug-target binding kinetics on target occupancy can be influenced by drug distribution and diffusion around the target, often referred to as "rebinding" or "diffusion-limited binding". This gives rise to a decreased decline of the drug-target complex concentration as a result of a locally higher drug concentration that arises around the target, which leads to prolonged target exposure to the drug. This phenomenon has been approximated by the steady-state approximation, assuming a steady-state concentration around the target. Recently, a rate-limiting step approximation of drug distribution and drug-target binding has been published. However, a comparison between both approaches has not been made so far. In this study, the rate-limiting step approximation has been rewritten into the same mathematical format as the steady-state approximation in order to compare the performance of both approaches for the investigation of the influence of drug-target binding kinetics on target occupancy. While both approximations clearly indicated the importance of kon and high target concentrations, it was shown that the rate-limiting step approximation is more accurate than the steady-state approximation, especially when dissociation is fast compared to association and distribution out of the binding compartment. It is therefore concluded that the new rate-limiting step approximation is to be preferred for assessing the influence of binding kinetics on local target site concentrations and target occupancy.